CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Noven Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Noven Pharmaceuticals, Inc.
11960 S.W. 144th Street
Phone: (305) 253-5099p:305 253-5099 Miami, FL  33186  United States Ticker: NOVN NOVN
This company was Merged or Acquired on 8/28/2009.
This company ceased filing statements with the SEC on 8/28/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Noven Pharmaceuticals, Inc. (Noven) is a specialty pharmaceutical company engaged in the research, development, manufacturing, licensing, marketing and sale of prescription pharmaceutical products. Its business is focused in three segments: Noven Transdermals, its transdermal drug delivery segment; Novogyne Pharmaceuticals (Novogyne), its women’s health joint venture with Novartis Pharmaceuticals Corporation (Novartis), and Noven Therapeutics, its specialty pharmaceutical segment. The Company’s primary commercialized products include prescription transdermal patches utilizing its proprietary transdermal drug delivery technology for use in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and in menopausal hormone therapy. In August 2009, Hisamitsu Pharmaceutical Co., Ltd. and Hisamitsu U.S., Inc. announced the completion of their acquisition of Noven. As a result of the transaction, Noven became a wholly owned subsidiary of Hisamitsu U.S., Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200912/31/2008YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Wayne P.Yetter 63 1/3/2008 8/9/2001
President, Chief Executive Officer, Director Peter C.Brandt 52 4/29/2008 4/29/2008
Chief Financial Officer, Vice President Michael D.Price 51 11/19/2007 11/19/2007
9 additional Officers and Directors records available in full report.

Business Names
Business Name
JDS Neuro, LLC
JDS Pharmaceuticals, LLC
Noven Alpha, LLC
6 additional Business Names available in full report.

General Information
Number of Employees: 610 (As of 12/31/2008)
Outstanding Shares: 25,082,398 (As of 7/31/2009)
Shareholders: 214
Stock Exchange: NASD
Federal Tax Id: 592767632
Fax Number: (305) 251-1887


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023